Citations (96)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Sina Nikayin, Eva Murphy, John H. Krystal & Samuel T. Wilkinson. (2022) Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion on Drug Safety 21:6, pages 777-787.
Read now
Read now
Jan Van Amsterdam & Wim Van Den Brink. (2022) Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opinion on Drug Safety 21:1, pages 83-94.
Read now
Read now
Yu-Li Liu, Francesco Bavato, An-Nie Chung, Tung-Hsia Liu, Yi-Lung Chen, Ming-Chyi Huang & Boris B. Quednow. (2021) Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence. The World Journal of Biological Psychiatry 22:9, pages 713-721.
Read now
Read now
Qun Zhao, Yuchen Mao, Xiaoming Li & Yu Zheng. (2021) Drug use characteristics and correlates of multiple risk behaviors among synthetic drug users. Journal of Substance Use 26:4, pages 420-426.
Read now
Read now
Gang Wang, Changsu Han, Chia-Yih Liu, Sandra Chan, Tadafumi Kato, Wilson Tan, Lili Zhang, Yu Feng & Chee H Ng. (2020) Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. Neuropsychiatric Disease and Treatment 16, pages 2943-2959.
Read now
Read now
Dusan Kolar. (2018) Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatric Disease and Treatment 14, pages 1513-1519.
Read now
Read now
Cheng-Chung Liu, Chun-Kuei Chen, Craig G. Smollin, Jiun-Hao Yu, Chen-June Seak & Hsien-Yi Chen. (2017) Pulseless ventricular tachycardia associated with chronic ketamine use. Clinical Toxicology 55:9, pages 1016-1017.
Read now
Read now
Yanhui Liao, Yi-lang Tang & Wei Hao. (2017) Ketamine and international regulations. The American Journal of Drug and Alcohol Abuse 43:5, pages 495-504.
Read now
Read now
Mohamed A Hendaus, Fatima A Jomha & Ahmed H Alhammadi. (2016) Is ketamine a lifesaving agent in childhood acute severe asthma?. Therapeutics and Clinical Risk Management 12, pages 273-279.
Read now
Read now
Michael H. Andreae, Evelyn Rhodes, Tyler Bourgoise, George M. Carter, Robert S. White, Debbie Indyk, Henry Sacks & Rosamond Rhodes. (2016) An Ethical Exploration of Barriers to Research on Controlled Drugs. The American Journal of Bioethics 16:4, pages 36-47.
Read now
Read now
Liang-Jen Wang, Shing-Fang Lu, Wen-Jiun Chou, Mian-Yoon Chong, Yao-Hsing Wang, Yu-Lian Hsieh, Yi-Hsuan Lee & Ching Chen. (2015) A family-oriented treatment program for youths with ketamine abuse and their caregivers: a pilot study in Taiwan. Neuropsychiatric Disease and Treatment 11, pages 1921-1927.
Read now
Read now
Yi-Chih Chen, Liang-Jen Wang, Shih-Ku Lin & Chih-Ken Chen. (2015) Neurocognitive Profiles of Methamphetamine Users: Comparison of Those With or Without Concomitant Ketamine Use. Substance Use & Misuse 50:14, pages 1778-1785.
Read now
Read now
Nagendra S Singh, Carlos A Zarate$suffix/text()$suffix/text(), Ruin Moaddel, Michel Bernier & Irving W Wainer. (2014) What is hydroxynorketamine and what can it bring to neurotherapeutics?. Expert Review of Neurotherapeutics 14:11, pages 1239-1242.
Read now
Read now
Articles from other publishers (83)
Sangeet Adhikari, Rahul Kumar, Erin M. Driver, Devin A. Bowes, Keng Tiong Ng, Juan Eduardo Sosa-Hernandez, Mariel Araceli Oyervides-Muñoz, Elda M. Melchor-Martínez, Manuel Martínez-Ruiz, Karina G. Coronado-Apodaca, Ted Smith, Aruni Bhatnagar, Brian J. Piper, Kenneth L. McCall, Roberto Parra-Saldivar, Leon P. Barron & Rolf U. Halden. (2023) Occurrence of Z-drugs, benzodiazepines, and ketamine in wastewater in the United States and Mexico during the Covid-19 pandemic. Science of The Total Environment 857, pages 159351.
Crossref
Crossref
Tomohiko Irie, Yuta Yanase, Yosuke Demizu, Makoto Usami & Ruri Kikura-Hanajiri. (2022) Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. Journal of Pharmacological Sciences 150:4, pages 233-243.
Crossref
Crossref
Patrycja Kleczkowska & Malgorzata Zaremba. 2022. Ketamine Revisited - New Insights into NMDA Inhibitors. Ketamine Revisited - New Insights into NMDA Inhibitors.
Yi-Ping Hsieh, Yun-Ju Wang, Ling-Yi Feng, Li-Tzy Wu & Jih-Heng Li. (2022) Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care. International Journal of Environmental Research and Public Health 19:14, pages 8363.
Crossref
Crossref
Roberta A. Downing. (2022) The One Health vision requires veterinarians and physicians to collaborate to prevent bioethical challenges created by restricted access to ketamine in low- and middle-income countries. Journal of the American Veterinary Medical Association, pages 1-6.
Crossref
Crossref
Leah Vines, Diana Sotelo, Allison Johnson, Evan Dennis, Peter Manza, Nora D. Volkow & Gene-Jack Wang. (2022) Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions. Intelligent Medicine 2:2, pages 61-68.
Crossref
Crossref
Maria Rosaria Varì, Giovanna Ricci, Marco Cavallo, Simona Pichini, Ascanio Sirignano & Silvia Graziano. (2022) Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance. Current Pharmaceutical Design 28:15, pages 1213-1220.
Crossref
Crossref
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch & Kevin W. Morin. (2022) Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating Ketamine Protocols with Trauma- and Attachment-Informed Psychotherapy. Psych 4:1, pages 119-141.
Crossref
Crossref
Joseph J. Palamar, Sakthi Kumar, Kevin H. Yang & Benjamin H. Han. (2022) Ketamine use in relation to depressive symptoms among high school seniors. The American Journal on Addictions 31:2, pages 100-107.
Crossref
Crossref
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, Pratap Chokka, Martin A. Katzman, Robert L. Tanguay & Atul Khullar. (2022) Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. CNS Drugs 36:3, pages 239-251.
Crossref
Crossref
Nigar Anzar, Shariq Suleman, Suhel Parvez & Jagriti Narang. (2022) A review on Illicit drugs and biosensing advances for its rapid detection. Process Biochemistry 113, pages 113-124.
Crossref
Crossref
Tony Szu-Hsien Lee, Yi-Hsuan Liu, Yun-Ju Huang, Wai-Kwong Tang, Yifan Wang, Sien Hu, Ching-Po Lin, Chiang-Shan Ray Li & Chia-Chun Hung. (2022) Clinical and behavior characteristics of individuals who used ketamine. Scientific Reports 12:1.
Crossref
Crossref
Yoosuk An, Seon Young Park & Ung Gu Kang. (2022) “Drugs of Abuse” as a “New Antidepressant”: - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential. Journal of Korean Neuropsychiatric Association 61:4, pages 243.
Crossref
Crossref
Mark D. Salter & Naren Gunja. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
381
414
.
Liang-Jen Wang & Sheng-Yu Lee. 2022. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
187
207
.
Grigorios N. Karakatsoulis & Konstantinos N. Fountoulakis. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders
261
282
.
Liang-Jen Wang & Sheng-Yu Lee. 2021. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
1
21
.
Wei J. Chen, Chi-Ya Chen, Shang-Chi Wu, Kevin Chien-Chang Wu, Susyan Jou, Yu-Chi Tung & Tzu-Pin Lu. (2021) The impact of Taiwan’s implementation of a nationwide harm reduction program in 2006 on the use of various illicit drugs: trend analysis of first-time offenders from 2001 to 2017. Harm Reduction Journal 18:1.
Crossref
Crossref
Alexandra Evans, Michael Krause, Samantha Leach, Morgan Levitas, Lucy Nguyen & Luke C. Short. (2021) Analysis of drug residue in needle-exchange syringes in Washington, D.C.. Forensic Science International 329, pages 111083.
Crossref
Crossref
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch & Kevin W. Morin. (2021) An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression. Frontiers in Psychiatry 12.
Crossref
Crossref
John Martin Corkery, Wan-Chu Hung, Hugh Claridge, Christine Goodair, Caroline S Copeland & Fabrizio Schifano. (2021) Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. Journal of Psychopharmacology 35:11, pages 1324-1348.
Crossref
Crossref
Ramadhan ORUCH, Ian F. PRYME, Ole B. FASMER & Anders LUND. (2021) Ketamine: use in psychiatry, its pharmacology and treatment following intoxication. Minerva Psychiatry 62:3.
Crossref
Crossref
Hu-Ming Chang, Po-Yu Chen, Chiu-Ping Fang, Tung-Hsia Liu, Chun-Te Wu, Yu-Chao Hsu, Hsiang-Wei Kuo, Yu-Li Liu & Ming-Chyi Huang. (2021) Increased Nectin-4 levels in chronic ketamine abusers and the relationship with lower urinary tract symptoms. Environmental Toxicology and Pharmacology 87, pages 103714.
Crossref
Crossref
Peng-Wei Wang, Cheng-Fang Yen, Hung-Chi Wu, Chih-Yao Hsu & Yu-Yi Yang. (2021) Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users. International Journal of Environmental Research and Public Health 18:18, pages 9567.
Crossref
Crossref
Wen‐Hsuan Pan, Kevin Chien‐Chang Wu, Chi‐Ya Chen, Yu‐Roo Chu, Shang‐Chi Wu, Susyan Jou, Tzu‐Pin Lu, Yu‐Chi Tung, Jui Hsu & Wei J. Chen. (2020) First‐time offenders for recreational ketamine use under a new penalty system in Taiwan: incidence, recidivism and mortality in national cohorts from 2009 to 2017. Addiction 116:7, pages 1770-1781.
Crossref
Crossref
Stephen D. Worrell & Thomas J. Gould. (2021) Therapeutic potential of ketamine for alcohol use disorder. Neuroscience & Biobehavioral Reviews 126, pages 573-589.
Crossref
Crossref
Tomohiko Irie, Daiju Yamazaki & Ruri Kikura-Hanajiri. (2021) A potential of methoxpropamine to be a widespread recreational drug: it blocks NMDA receptors and inhibits NMDA receptor-mediated synaptic transmission in a brain preparation of mice. Forensic Toxicology 39:2, pages 474-480.
Crossref
Crossref
Kai Zhang & Kenji Hashimoto. 2021. New Rapid-acting Antidepressants. New Rapid-acting Antidepressants
1
16
.
Christopher Tremonti & Paul S. Haber. 2021. Textbook of Addiction Treatment. Textbook of Addiction Treatment
637
654
.
Cheng-Fang Yen, Huang-Chi Lin, Chih-Hung Ko, Hung-Chi Wu, Chih-Yao Hsu & Peng-Wei Wang. (2020) Sleep quality among individuals with ketamine use and the mediating role of craving. Scientific Reports 10:1.
Crossref
Crossref
Joydip Das. (2020) Repurposing of Drugs–The Ketamine Story. Journal of Medicinal Chemistry 63:22, pages 13514-13525.
Crossref
Crossref
Doaa M. El Shehaby, Reham I El-Mahdy, Asmaa M. Ahmed, Ahmed Hosny & Nessren M. Abd el-Rady. (2020) Neurobehavioral, testicular and erectile impairments of chronic ketamine administration: Pathogenesis and ameliorating effect of N-acetyl cysteine. Reproductive Toxicology 96, pages 57-66.
Crossref
Crossref
Ling-Yi Feng & Jih-Heng Li. (2020) New psychoactive substances in Taiwan: challenges and strategies. Current Opinion in Psychiatry 33:4, pages 306-311.
Crossref
Crossref
Paulo R. Shiroma, Paul Thuras, Joseph Wels, C. Sophia Albott, Christopher Erbes, Susannah Tye & Kelvin O. Lim. (2020) A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Translational Psychiatry 10:1.
Crossref
Crossref
Nur Khalisah Kaswan, Nurul Syazwani Mohd Suhaimi, Noor Aishah Mohammed Izham, Tengku Azam Shah Tengku Mohamad, Mohd Roslan Sulaiman & Enoch Kumar Perimal. (2020) Cardamonin inhibits nitric oxide production modulated through NMDA receptor in LPS-Induced SH-SY5Y cell in vitro model. Life Sciences, Medicine and Biomedicine 4:9.
Crossref
Crossref
Cheolmin Shin & Yong-Ku Kim. (2020) Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives. Psychiatry Investigation 17:3, pages 181-192.
Crossref
Crossref
Ling‐Yi Feng, Kiyoshi Wada, Heesun Chung, Eunyoung Han & Jih‐Heng Li. (2019) Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan. The Kaohsiung Journal of Medical Sciences 36:2, pages 135-142.
Crossref
Crossref
Vinita Singh, JackWilliams Shteamer, JonathanSeth Lowe & MaysonAugustus Callaway. (2020) Central sensitization and its role in chronic pain: What can ketamine do?. Indian Journal of Pain 34:1, pages 3.
Crossref
Crossref
Chih-Jen Wang, Li-Ling Huang, Yu-San Chang, Ching-Hong Tsai, Yu-Hsuan Wu, Yi-Fan Lin, Wen-Huei Lin & Kuan-Ying Hsieh. (2020) Correlates Related to Probable Common Mental Disorders among Ketamine Users: Cognitive and Urinary Impairments. Taiwanese Journal of Psychiatry 34:4, pages 181.
Crossref
Crossref
Chen Lin, Bo-Yu Wong, Men-Tzung Lo, Yu-Chuan Chiu & Yu-Hsuan Lin. (2020) Development of an addiction index and delineation 15-year trends of illicit drugs from the Taiwan national drug enhancement database. Journal of Psychiatric Research 120, pages 131-136.
Crossref
Crossref
Ming-Chyi Huang & Shih-Ku Lin. 2020. Ketamine. Ketamine
1
14
.
Chao-Ming Chang, Tat Leong Wu, Te-Tien Ting, Chuan-Yu Chen, Lien-Wen Su & Wei J. Chen. (2019) Mis-anaesthetized society: expectancies and recreational use of ketamine in Taiwan. BMC Public Health 19:1.
Crossref
Crossref
Vicente Esparza-Villalpando, Ruben Ascencio-Padilla, Amaury Pozos-Guillen, Fernando Pozos-Guillen, Jose Antonio Hidalgo-Hurtado & Daniel Chavarria-Bolaños. (2019) Local Ketamine Improves Postoperative Analgesia After Third Molar Surgery. Journal of Oral and Maxillofacial Surgery 77:12, pages 2386-2400.
Crossref
Crossref
Qing Li, Hui-ran Wu, Shu-juan Fan, De-xiang Liu, Hong Jiang, Qian Zhang & Fang Pan. (2019) The effects of sub-anesthetic ketamine plus ethanol on behaviors and apoptosis in the prefrontal cortex and hippocampus of adolescent rats. Pharmacology Biochemistry and Behavior 184, pages 172742.
Crossref
Crossref
Mei-Yi Lee, Yu-Ching Hsiao, Ming-Huan Chan & Hwei-Hsien Chen. (2019) Lamotrigine attenuates the motivation to self-administer ketamine and prevents cue- and prime-induced reinstatement of ketamine-seeking behavior in rats. Drug and Alcohol Dependence 194, pages 257-263.
Crossref
Crossref
Liang-Jen Wang, Mei-Yen Chen, Chin-Yin Lin, Mian-Yoon Chong, Wen-Jiun Chou, Yu-Han You, Chih-Pu Tsai, Yi-Syuan Chen & Shing-Fang Lu. (2018) Difference in long-term relapse rates between youths with ketamine use and those with stimulants use. Substance Abuse Treatment, Prevention, and Policy 13:1.
Crossref
Crossref
Ming-Chyi Huang, Lian-Yu Chen, Hu-Ming Chang, Xiao-Yu Liang, Chih-Ken Chen, Wan-Ju Cheng & Ke Xu. (2018) Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence. Frontiers in Psychiatry 9.
Crossref
Crossref
Daiying Zuo, Yumiao Liu, Zi Liu, Jiahui Cui, Xuejiao Zhou, Yang Liu, Zengqiang Li & Yingliang Wu. (2018) Alcohol aggravates ketamine-induced behavioral, morphological and neurochemical alterations in adolescent rats: The involvement of CREB-related pathways. Behavioural Brain Research 349, pages 80-90.
Crossref
Crossref
R. B. Raffa, J. V. PergolizziJr.Jr. & R. TaylorJr.Jr.. (2017) The rapid‐onset antidepressant effect of ketamine: More surprises?. Journal of Clinical Pharmacy and Therapeutics 43:2, pages 308-311.
Crossref
Crossref
Yu Shi, Jiejing Li, Chunjiang Chen, Yongwu Xia, Yanxi Li, Pan Zhang, Ying Xu, Tingyu Li, Weihui Zhou & Weihong Song. (2018) Ketamine Modulates Zic5 Expression via the Notch Signaling Pathway in Neural Crest Induction. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
Yong-Ku KimCheolmin Shin. (2018) Rapid-Acting Antidepressant Effect of Ketamine and Its Clinical Application. Journal of Korean Neuropsychiatric Association 57:2, pages 108.
Crossref
Crossref
Samuel T. Wilkinson, Robert B. Ostroff, Rachel B. Katz & John H. Krystal. 2018. Understanding Depression. Understanding Depression
223
239
.
Qing Liu, Tian-Yong Xu, Zhi-Bi Zhang, Chi-Kwan Leung, Ding-Yun You, Shang-Wen Wang, Shuai Yi, Qiang Jing, Run-Fang Xie, Huifang-Jie Li & Xiao-Feng Zeng. (2017) Effects of co-administration of ketamine and ethanol on the dopamine system via the cortex-striatum circuitry. Life Sciences 179, pages 1-8.
Crossref
Crossref
Ilina Singh, Celia Morgan, Valerie Curran, David Nutt, Anne Schlag & Rupert McShane. (2017) Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry 4:5, pages 419-426.
Crossref
Crossref
Geoffrey Littlejohn & Emma Guymer. (2017) Modulation of NMDA Receptor Activity in Fibromyalgia. Biomedicines 5:4, pages 15.
Crossref
Crossref
Sarah E. Grady, Travis A. Marsh, Allison Tenhouse & Kelsey Klein. (2017) Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature. Mental Health Clinician 7:1, pages 16-23.
Crossref
Crossref
Udo Bonnet. (2017) How much alcohol is in ketamine's antidepressant action?. Life Sciences 168, pages 54-57.
Crossref
Crossref
S.C. Cartágenes, L.M.P. Fernandes, E. Fontes de AndradeJr.Jr., R.D. Prediger & C.S.F. Maia. 2017. Addictive Substances and Neurological Disease. Addictive Substances and Neurological Disease
373
382
.
Frank Anthony MyersJr.Jr., Martin H. Bluth & Wellman W. Cheung. (2016) Ketamine. Clinics in Laboratory Medicine 36:4, pages 721-744.
Crossref
Crossref
Matthew Umholtz, John Cilnyk, Christopher K. Wang, Jahan Porhomayon, Leili Pourafkari & Nader D. Nader. (2016) Postanesthesia emergence in patients with post-traumatic stress disorder. Journal of Clinical Anesthesia 34, pages 3-10.
Crossref
Crossref
Eunyoung Han, Nam ji Kwon, Ling-Yi Feng, Jih-Heng Li & Heesun Chung. (2016) Illegal use patterns, side effects, and analytical methods of ketamine. Forensic Science International 268, pages 25-34.
Crossref
Crossref
R. Moaddel, M. Sanghvi, A. Ramamoorthy, K. Jozwiak, N. Singh, C. Green, K. O’Loughlin, M. Torjman & I.W. Wainer. (2016) Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats. Journal of Pharmaceutical and Biomedical Analysis 127, pages 3-8.
Crossref
Crossref
Sean Sassano-Higgins, Dave Baron, Grace Juarez, Neevon Esmaili & Mark Gold. (2016) A REVIEW OF KETAMINE ABUSE AND DIVERSION. Depression and Anxiety 33:8, pages 718-727.
Crossref
Crossref
D. Jeffrey Newport, Alan F. Schatzberg & Charles B. Nemeroff. (2016) WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?. Depression and Anxiety 33:8, pages 685-688.
Crossref
Crossref
Melvyn W.B. Zhang, Roger C.M. Ho & Roger S. Mcintyre. (2016) The `WikiGuidelines' smartphone application: Bridging the gaps in availability of evidence-based smartphone mental health applications. Technology and Health Care 24:4, pages 587-590.
Crossref
Crossref
Roger C. M. Ho & Melvyn W. Zhang. (2018) Ketamine as a rapid antidepressant: the debate and implications. BJPsych Advances 22:4, pages 222-233.
Crossref
Crossref
Gin S. Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A. Frye, Michael Gitlin, Sidney H. Kennedy, Terence A. Ketter, Raymond W. Lam, Rupert McShane, Alex J. Mitchell, Michael J. Ostacher, Sakina J. Rizvi, Michael E. Thase & Mauricio Tohen. (2018) Ketamine: stimulating antidepressant treatment?. BJPsych Open 2:3, pages e5-e9.
Crossref
Crossref
Adam L. Halberstadt, Natalia Slepak, James Hyun, Mahalah R. Buell & Susan B. Powell. (2016) The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology 233:7, pages 1215-1225.
Crossref
Crossref
Luís Félix, Luís Antunes, Sónia Campos, Carlos Venâncio & Ana Maria Coimbra. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
672
680
.
Sijie Tan, Ju Zou, Meixiang Li & David T. Yew. (2016) Chronic effects of ketamine on gene expression changes in neurotransmitter receptors and regulators-A PCR-array study. Molecular & Cellular Toxicology 11:4, pages 395-400.
Crossref
Crossref
Juanjuan Tang, Wenda Xue, Baomei Xia, Li Ren, Weiwei Tao, Chang Chen, Hailou Zhang, Ruyan Wu, Qisheng Wang, Haoxin Wu, Jinao Duan & Gang Chen. (2015) Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Scientific Reports 5:1.
Crossref
Crossref
Kaitlin E. DeWilde, Cara F. Levitch, James W. Murrough, Sanjay J. Mathew & Dan V. Iosifescu. (2015) The promise of ketamine for treatment-resistant depression: current evidence and future directions. Annals of the New York Academy of Sciences 1345:1, pages 47-58.
Crossref
Crossref
Ke Xu & Robert H Lipsky. (2014)
Repeated ketamine administration alters
N
-methyl-
d
-aspartic acid receptor subunit gene expression: Implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans
. Experimental Biology and Medicine 240:2, pages 145-155.
Crossref
Crossref
Yao Zhang, Zaifeng Xu, Sheng Zhang, Alethea Desrosiers, Richard S. Schottenfeld & Marek C. Chawarski. (2014) Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. Journal of Psychiatric Research 53, pages 99-102.
Crossref
Crossref
Angela Yu-Chen Lin, Wan-Ning Lee & Xiao-Huan Wang. (2014) Ketamine and the metabolite norketamine: Persistence and phototransformation toxicity in hospital wastewater and surface water. Water Research 53, pages 351-360.
Crossref
Crossref
Carlos Lledo-Fernandez, Pat Pollard & Senee Kruanetr. (2013) Electroanalytical Sensing of Ketamine Using Electrogenerated Chemiluminescence. Journal of The Electrochemical Society 161:1, pages H36-H40.
Crossref
Crossref
Luís M. Félix, Luís M. Antunes & Ana M. Coimbra. (2014) Ketamine NMDA receptor-independent toxicity during zebrafish (Danio rerio) embryonic development. Neurotoxicology and Teratology 41, pages 27-34.
Crossref
Crossref
Wei J. Chen, Te-Tien Ting, Chao-Ming Chang, Ying-Chun Liu & Chuan-Yu Chen. (2013) Ketamine use among regular tobacco and alcohol users as revealed by respondent-driven sampling in Taipei: Prevalence, expectancy, and users' risky decision making. Journal of Food and Drug Analysis 21:4, pages S102-S105.
Crossref
Crossref
Wen-Jing Yu, Wen-Ing Tsay & Jih-Heng Li. (2013) Current status of substance abuse and HIV in Taiwan. Journal of Food and Drug Analysis 21:4, pages S27-S32.
Crossref
Crossref
R. Pal, S. Balt, E. Erowid, F. Erowid, M.J. Baggott, J. Mendelson & G.P. Galloway. (2013) Ketamine is associated with lower urinary tract signs and symptoms. Drug and Alcohol Dependence 132:1-2, pages 189-194.
Crossref
Crossref
Hilary J. Burch, Elizabeth J. Clarke, Alison M. Hubbard & Michael Scott-Ham. (2013) Concentrations of drugs determined in blood samples collected from suspected drugged drivers in England and Wales. Journal of Forensic and Legal Medicine 20:4, pages 278-289.
Crossref
Crossref
Yangyang Zhang, Changli Lu, Jun Zhang, Li Hu, Hui Song, Jing Li & Lin Kang. (2013) Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. Addictive Behaviors 38:1, pages 1424-1430.
Crossref
Crossref
Qijian Deng, Quansheng Tang, Richard S. Schottenfeld, Wei Hao & Marek C. Chawarski. (2012) Drug use in rural China: a preliminary investigation in Hunan Province. Addiction 107:3, pages 610-613.
Crossref
Crossref